Jim Simons Nektar Therapeutics Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Nektar Therapeutics stock. As of the latest transaction made, Renaissance Technologies LLC holds 4,620,681 shares of NKTR stock, worth $5.73 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,620,681

Previous 5,325,475 13.23%

Holding current value

$5.73 Million

Previous $3.01 Million 43.47%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.49 - $0.96 $345,349 - $676,602	-704,794 Reduced 13.23%	4,620,681 $4.32 Million
Q4 2023 Feb 13, 2024	BUY	$0.42 - $0.57 $763,893 - $1.04 Million	1,818,794 Added 51.87%	5,325,475 $3.01 Million
Q3 2023 Nov 14, 2023	SELL	$0.51 - $1.05 $298,350 - $614,250	-585,000 Reduced 14.3%	3,506,681 $2.09 Million
Q2 2023 Aug 11, 2023	BUY	$0.53 - $1.03 $576,632 - $1.12 Million	1,087,985 Added 36.22%	4,091,681 $2.35 Million
Q1 2023 May 12, 2023	BUY	$0.64 - $3.15 $1.85 Million - $9.09 Million	2,886,585 Added 2464.83%	3,003,696 $2.11 Million

Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $237,735 - $501,235	117,111 New	117,111 $265,000
Q3 2019 Nov 13, 2019	SELL	$16.91 - $36.27 $5.53 Million - $11.9 Million	-327,048 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$31.0 - $36.3 $3.77 Million - $4.41 Million	121,600 Added 59.19%	327,048 $11.6 Million
Q1 2019 May 14, 2019	SELL	$31.58 - $46.35 $6.21 Million - $9.11 Million	-196,500 Reduced 48.89%	205,448 $6.9 Million
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $12.2 Million - $22.8 Million	401,948 New	401,948 $13.2 Million

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account